inclusion criteria: 1. male or female aged ≥ 40 years; 2. symptomatic adults with confirmed covid-19 (sars-cov-2 pcr positive) for at least 24 hrs. and no more than 7 days: by report or observation, including one or more of the following: temperature ≥ 38°c (≥100.4°f), chills or shivering, cough, difficulty breathing, fatigue, headache, muscle or body ache, anosmia (loss of smell) and/or dysgeusia (loss of taste), gi symptoms (nausea and/or vomiting); (3a) aged ≥70 years or above, presence of concomitant comorbidity not required for inclusion or (3b) aged ≥40 to \<70 years, and presence of at least one of the following concomitant comorbidities by report, history, or observation: * cardiovascular diseases (e.g., hypertension, coronary artery diseases, congestive heart failure, symptomatic arrhythmia, transient brain ischemia, stroke) * chronic respiratory diseases (e.g., chronic obstructive pulmonary disease (copd), asthma, pulmonary fibrosis) * obesity (bmi \>30 kg/m\^2) * type 2 diabetes * cancer (participant reported: stable \>6 months as per treating doctor/oncologist) * autoimmune diseases (t1d, ra, pa, ms, ibd, ad, ss, ht, sle) (4) participant is considered suitable for continued management in the out-patient setting. (5) non-pregnant non-breastfeeding women of reproductive age group not planning pregnancy and/or adopting advised contraception during the study and for 3 months after the last dose of study medication.

inclusion criteria: 1. male or female aged ≥ 40 years; 2. symptomatic adults with confirmed covid-19 (sars-cov-2 pcr positive) for at least 24 hrs. and no more than 7 days: by report or observation, including one or more of the following: temperature ≥ 38°c (≥100.4°f), chills or shivering, cough, difficulty breathing, fatigue, headache, muscle or body ache, anosmia (loss of smell) and/or dysgeusia (loss of taste), gi symptoms (nausea and/or vomiting); (3a) aged ≥70 years or above, presence of concomitant comorbidity not required for inclusion or (3b) aged ≥40 to \<70 years, and presence of at least one of the following concomitant comorbidities by report, history, or observation: * cardiovascular diseases (e.g., hypertension, coronary artery diseases, congestive heart failure, symptomatic arrhythmia, transient brain ischemia, stroke) * chronic respiratory diseases (e.g., chronic obstructive pulmonary disease (copd), asthma, pulmonary fibrosis) * obesity (bmi \>30 kg/m\^2) * type 2 diabetes * cancer (participant reported: stable \>6 months as per treating doctor/oncologist) * autoimmune diseases (t1d, ra, pa, ms, ibd, ad, ss, ht, sle) (4) participant is considered suitable for continued management in the out-patient setting. (5) non-pregnant non-breastfeeding women of reproductive age group not planning pregnancy and/or adopting advised contraception during the study and for 3 months after the last dose of study medication.

inclusion criteria: male or female aged ≥ 40 years; symptomatic adults with confirmed covid-19 (sars-cov-2 pcr positive) for at least 24 hrs. and no more than 7 days: by report or observation, including one or more of the following: temperature ≥ 38°c (≥100.4°f), chills or shivering, cough, difficulty breathing, fatigue, headache, muscle or body ache, anosmia (loss of smell) and/or dysgeusia (loss of taste), gi symptoms (nausea and/or vomiting); (3a) aged ≥70 years or above, presence of concomitant comorbidity not required for inclusion or (3b) aged ≥40 to <70 years, and presence of at least one of the following concomitant comorbidities by report, history, or observation: cardiovascular diseases (e.g., hypertension, coronary artery diseases, congestive heart failure, symptomatic arrhythmia, transient brain ischemia, stroke) chronic respiratory diseases (e.g., chronic obstructive pulmonary disease (copd), asthma, pulmonary fibrosis) obesity (bmi >30 kg/m^2) type 2 diabetes cancer (participant reported: stable >6 months as per treating doctor/oncologist) autoimmune diseases (t1d, ra, pa, ms, ibd, ad, ss, ht, sle) (4) participant is considered suitable for continued management in the out-patient setting. (5) non-pregnant non-breastfeeding women of reproductive age group not planning pregnancy and/or adopting advised contraception during the study and for 3 months after the last dose of study medication.

inclusion criteria: male or female aged ≥ 40 years; symptomatic adults with confirmed covid-19 (sars-cov-2 pcr positive) for at least 24 hrs. and no more than 7 days: by report or observation, including one or more of the following: temperature ≥ 38°c (≥100.4°f), chills or shivering, cough, difficulty breathing, fatigue, headache, muscle or body ache, anosmia (loss of smell) and/or dysgeusia (loss of taste), gi symptoms (nausea and/or vomiting); (3a) aged ≥70 years or above, presence of concomitant comorbidity not required for inclusion or (3b) aged ≥40 to <70 years, and presence of at least one of the following concomitant comorbidities by report, history, or observation: cardiovascular diseases (e.g., hypertension, coronary artery diseases, congestive heart failure, symptomatic arrhythmia, transient brain ischemia, stroke) chronic respiratory diseases (e.g., chronic obstructive pulmonary disease (copd), asthma, pulmonary fibrosis) obesity (bmi >30 kg/m^2) type 2 diabetes cancer (participant reported: stable >6 months as per treating doctor/oncologist) autoimmune diseases (t1d, ra, pa, ms, ibd, ad, ss, ht, sle) (4) participant is considered suitable for continued management in the out-patient setting. (5) non-pregnant non-breastfeeding women of reproductive age group not planning pregnancy and/or adopting advised contraception during the study and for 3 months after the last dose of study medication.

inclusion criteria: 1. male or female aged ≥ 40 years; 2. symptomatic adults with confirmed covid-19 (sars-cov-2 pcr positive) for at least 24 hrs. and no more than 7 days: by report or observation, including one or more of the following: temperature ≥ 38°c (≥100.4°f), chills or shivering, cough, difficulty breathing, fatigue, headache, muscle or body ache, anosmia (loss of smell) and/or dysgeusia (loss of taste), gi symptoms (nausea and/or vomiting); (3a) aged ≥70 years or above, presence of concomitant comorbidity not required for inclusion or (3b) aged ≥40 to <70 years, and presence of at least one of the following concomitant comorbidities by report, history, or observation: - cardiovascular diseases (e.g., hypertension, coronary artery diseases, congestive heart failure, symptomatic arrhythmia, transient brain ischemia, stroke) - chronic respiratory diseases (e.g., chronic obstructive pulmonary disease (copd), asthma, pulmonary fibrosis) - obesity (bmi >30 kg/m^2) - type 2 diabetes - cancer (participant reported: stable >6 months as per treating doctor/oncologist) - autoimmune diseases (t1d, ra, pa, ms, ibd, ad, ss, ht, sle) (4) participant is considered suitable for continued management in the out-patient setting. (5) non-pregnant non-breastfeeding women of reproductive age group not planning pregnancy and/or adopting advised contraception during the study and for 3 months after the last dose of study medication.

inclusion criteria: 1. male or female aged ≥ 40 years; 2. symptomatic adults with confirmed covid-19 (sars-cov-2 pcr positive) for at least 24 hrs. and no more than 7 days: by report or observation, including one or more of the following: temperature ≥ 38°c (≥100.4°f), chills or shivering, cough, difficulty breathing, fatigue, headache, muscle or body ache, anosmia (loss of smell) and/or dysgeusia (loss of taste), gi symptoms (nausea and/or vomiting); (3a) aged ≥70 years or above, presence of concomitant comorbidity not required for inclusion or (3b) aged ≥40 to <70 years, and presence of at least one of the following concomitant comorbidities by report, history, or observation: - cardiovascular diseases (e.g., hypertension, coronary artery diseases, congestive heart failure, symptomatic arrhythmia, transient brain ischemia, stroke) - chronic respiratory diseases (e.g., chronic obstructive pulmonary disease (copd), asthma, pulmonary fibrosis) - obesity (bmi >30 kg/m^2) - type 2 diabetes - cancer (participant reported: stable >6 months as per treating doctor/oncologist) - autoimmune diseases (t1d, ra, pa, ms, ibd, ad, ss, ht, sle) (4) participant is considered suitable for continued management in the out-patient setting. (5) non-pregnant non-breastfeeding women of reproductive age group not planning pregnancy and/or adopting advised contraception during the study and for 3 months after the last dose of study medication.